S1021 MELD-Na Score Prognostic Utility and Implementation in Clinically Relevant Outcomes of Patients With SARS-CoV-2

Abstract

INTRODUCTION: In December 2019, a new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, causing a devastating respiratory illness. The model for end-stage liver disease-sodium (MELD-Na) score can be used to predict mortality in patients with liver disease. METHODS: This is a single center retrospective cohort study of patients diagnosed with 2019 Novel Coronavirus (SARS-CoV-2) between March of 2020 and May of 2020. Our study aimed to validate the utility of the MELD-Na score in predicting mortality in patients diagnosed with SARS-CoV-2. The primary outcome includes all cause in-hospital mortality. The secondary outcomes include hospital length-of-stay, ICU admission rate and ICU length of stay. RESULTS: MELD-Na was evaluated in a cohort of 71 patients. The analysis included 31/71 (43.66%) men with a mean age of 66 ± 16 years. The median MELD-Na score was 27.9. A cutoff value of 30 was assigned to stratify patients into low and high groups. Mortality rate for patients with a MELD-Na score (<30) was 18.6% and MELD-Na score (>30) was 47.62% (P = 0.0154). Hospital length of stay for patients with a low score was 5.74 days versus 8.42 days (P = 0.1644). Patient admission rates to the ICU were analyzed, in the low score group 20.93% of patients were admitted to the ICU versus 47.62% (P = 0.0086). ICU length of stay for patients with a low score was 8.44 days versus 12.31 days (P = 0.2566). CONCLUSION: MELD-Na is a valid prognostic score that can be used as a reliable predictor of morbidity and mortality in patients with PCR-confirmed SARS-CoV-2.